drugset / Trial / NCT06594211
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of allogeneic anti-BCMA/GPRC5D bispecific chimeric antigen receptor natural killer (CAR-NK) cells (ACT-001) in patients with refractory or relapsed multiple myeloma (r/r MM).
Timeline
- Start
- 2024-10-09
- Primary completion
- 2028-10-09
- Completion
- 2028-10-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACT001 | Unknown | 1e+08 cells | — |
| Subject | ACT001 | Unknown | 3e+08 cells | — |
| Subject | ACT001 | Unknown | 9e+08 cells | — |